
Shanghai Lechun Biotechnology
Single-use bioprocessing solutions for the biopharmaceutical industry.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | CNY200m | Series C | |
Total Funding | 000k |
Related Content
Shanghai LePure Biotech Co., Ltd. is a provider of single-use bioprocessing solutions for the biopharmaceutical industry. Founded in 2011 by Chairwoman Qin Sunxing and co-founder and CEO Frank Wang, the company was one of the first domestic providers of single-use consumables and equipment for biopharmaceutical companies in China. LePure Biotech offers a comprehensive product suite that covers the entire biopharmaceutical process, from upstream cell cultivation to downstream separation and purification, and final drug formulation and filling.
The company's offerings include single-use bags, tubing and assemblies, bioreactors, filters, and fluid management equipment. Through strategic acquisitions, LePure has expanded its portfolio to include filtration and purification solutions, as well as cell culture media. In November 2022, the company acquired QuaCell Biotechnology, entering the cell culture media business. This was followed by the acquisition of GeShi Fluid in January 2023, which has over 20 years of experience in filtration and purification technology, significantly strengthening LePure's position in the filtration market.
LePure Biotech operates with a vertically integrated manufacturing model, controlling the process from in-house film extrusion to final product assembly to ensure quality and consistency. The company serves biopharmaceutical clients, including those in monoclonal antibody, vaccine, and cell therapy sectors, and has provided solutions to over 600 biopharmaceutical companies in China, while also exporting to the USA, Singapore, South Korea, and Germany. The firm has received significant investment from world-renowned investors. In January 2023, it closed a Series C financing round co-led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management. These funds are intended to accelerate product innovation and support overseas expansion.
Keywords: single-use bioprocessing, biopharmaceutical consumables, fluid management, cell culture media, pharmaceutical filtration, bioprocess solutions, single-use bags, bioreactors, purification technology, macromolecular drugs, drug development, antibody production, vaccine manufacturing, cell therapy, aseptic solutions, sterile liquid handling, bioproduction, laboratory consumables, GMP compliance, custom bioprocess assemblies